Table 1.
Comparison of baseline data between the groups.
| Cinobufacini group (n = 31) | Epirubicin group (n = 25) | P value | |
|---|---|---|---|
| Age | 54.1 ± 11.2 | 58.1 ± 12.4 | 0.583 |
| Sex | 0.120 | ||
| M | 27 (87.1) | 25 (100) | |
| F | 4 (12.9) | 0 (0) | |
| BCLC stage | 0.611 | ||
| B | 17 (54.8) | 12 (48.0) | |
| C | 14 (45.2) | 13 (52.0) | |
| Child-Pugh stage | 0.443 | ||
| A | 26 (83.9) | 23 (92.0) | |
| B | 5 (16.1) | 2 (8.0) | |
| ECOG score | 0.981 | ||
| 0 | 13 (41.9) | 10 (40.0) | |
| 1 | 17 (54.8) | 14 (56.0) | |
| 2 | 1 (3.2) | 1 (4.0) | |
| AFP | 0.386 | ||
| <400 | 15 (48.4) | 15 (60.0) | |
| ≥400 | 16 (51.6) | 10 (40.0) | |
| HBsAg | 0.153 | ||
| + | 28 (90.3) | 18 (72.0) | |
| − | 3 (9.7) | 7 (28.0) | |
| TB | 16.9 ± 7.8 | 16.3 ± 7.6 | 0.653 |
| ALT | 46.3 ± 29.2 | 51.2 ± 44.0 | 0.351 |
| Tumor size | 12.1 ± 3.2 | 11.8 ± 4.0 | 0.760 |